CTRI/2024/06/068514
Not yet recruiting
Phase 4
A post market clinical follow up prospective study to evaluate safety and performance of Sodium Hyaluronate Ophthalmic Solution - NI
Kilitch Healthcare India Ltd.0 sites0 target enrollmentTBD
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Kilitch Healthcare India Ltd.
- Status
- Not yet recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Subjects who are able to give voluntary, written informed consent to participate in this study.
- •Subjects who experience eye dryness, eye soreness/ burning, irritative sensation and discomfort
- •of eyes due to the continuous use of computer/ TV/ exposed pollution/ dry environment.
Exclusion Criteria
- •Anyone with known allergic reaction to Sodium Hyaluronate Ophthalmic Solution.
- •Subjects with existing eye infection.
- •History of ocular surgery. History or active signs of severe or serious ocular conditions such as
- •inflammatory corneal ulcers, recurrent erosions, and uveitis at any time.
- •Patients participating in any another clinical trial during study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 4
A post market clinical follow up study of Sterile Hydroxy Propyl Methyl Cellulose Eye DropsHealth Condition 1: H579- Unspecified disorder of eye and adnexaCTRI/2024/02/062930Amanta Healthcare Limited65
Not yet recruiting
Phase 4
A study to evaluate safety and performance of Hydroxypropyl Methylcellulose Eye DropsCTRI/2024/06/069121Kilitch Healthcare India Ltd.
Completed
Phase 4
Study to evaluate safety and performance of Eye Preparations - Carmellose Sodium Eye DropsHealth Condition 1: H28- Cataract in diseases classified elsewhereCTRI/2022/07/043791STERICON PHARMA PRIVATE LIMITED54
Completed
Phase 4
The purpose of the study is to evaluate safety and performance of Eye Preparations - HPMC EYE WASH (Hydroxy Propyl Methyl Cellulose Eye Wash )Health Condition 1: H28- Cataract in diseases classified elsewhereCTRI/2022/07/043794STERICON PHARMA PRIVATE LIMITED72
Completed
Phase 4
A post market clinical follow up study of Sodium Hyaluronate 0.2% Eye DropsHealth Condition 1: H579- Unspecified disorder of eye and adnexaCTRI/2024/02/062929Amanta Healthcare Limited54